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he Growing Problem
f Obesity and the Heart
he Plot “Thickens”*
heldon E. Litwin, MD, FACC
alt Lake City, Utah
here is widespread recognition of the developing epidemic
f obesity worldwide (1). Obesity imparts a major risk for
he secondary complications of diabetes and is associated
ith increased cardiovascular morbidity and mortality (2).
he Framingham investigators found that after adjustment
or known coronary risk factors, the relative risk of devel-
ping heart failure over 14 years of follow-up increased by
% to 7% for each increment of one in body mass index
BMI) (3).
See page 611
The link between obesity and heart failure has led to a
idely held notion that there is a cardiomyopathy of obesity
4). Despite the broad acceptance of this concept, the
iterature is ambiguous about the existence of a specific
besity-related cardiomyopathy and the molecular and bio-
hemical characteristics of such a condition. There are
ultiple possible mechanisms by which obesity could con-
ribute to heart failure: 1) obesity causes accumulation of
ipid in or around myocytes, producing lipotoxicity (5); 2)
besity indirectly causes right heart failure because of restrictive
ung disease or sleep-disordered breathing; 3) obesity predis-
oses to maladies such as valvular heart disease, hyperten-
ion, and diabetes, and these conditions secondarily cause
entricular dysfunction; 4) obesity leads to other diseases
i.e., hypertension, hyperlipidemia, and diabetes), which
hen act to impair cardiac function by promoting the
evelopment of ischemic heart disease; 5) obesity leads to
etabolic changes that impair energy production or increase
xidative free radical production in the heart (6); 6) obesity is
chronic inflammatory state, and the inflammatory cytokines
mpair cardiac function or cause fibrosis (7); and 7) obesity
imply increases the workload on the heart (i.e., high cardiac
utput) and thus unmasks latent ventricular dysfunction of
ther etiologies, or gradually causes heart failure because of
hronic overload.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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eterans Affairs.In the Framingham cohort, a reduced left ventricular
LV) ejection fraction was present in the majority (66%) of
he obese patients who had an echocardiogram performed
ithin 30 days of the diagnosis of heart failure (3). How-
ver, this study did not provide data on how many of the
atients who developed heart failure had evidence of isch-
mic heart disease. This is an important consideration
ecause obesity may predispose to heart failure because it is
risk factor for atherosclerosis rather than a direct cause of
eart failure. Moreover, the mean age of the patients in that
tudy was 55 years—a population that has a significant risk
or coronary disease, even after adjustment for baseline risk
actors. In contrast, at least two recent studies have found
hat younger (mean ages, 44 and 31 years, respectively)
nd otherwise healthy patients with various degrees of
besity have normal LV ejection fractions (8,9). Nonethe-
ess, both groups reported reductions in LV tissue Doppler
elocities and/or strain indices that correlated with the
everity of obesity. Wong et al. (8) also found that the LV
issue Doppler velocities in both systole and diastole corre-
ated moderately with exercise capacity. Thus, it seems that
ncomplicated obesity is associated with subclinical LV
ysfunction that can be shown with sensitive measurement
echniques.
The Framingham Heart Study criteria for heart failure
ay define overlapping populations with left, right, or
iventricular heart failure (10). Because obesity is the main
isk factor for obstructive sleep apnea, it is important to also
onsider right ventricular (RV) dysfunction as a possible
echanism of heart failure in the obese population. Prior
tudies have not directly assessed the right ventricle in
everely obese patients. In this issue of the Journal, Wong
t al. (11) assessed RV function using conventional echocar-
iographic measures (RV volumes and RV ejection fraction)
nd newer approaches based on tissue Doppler measure-
ents of long-axis tricuspid annulus velocities and RV
train indices. These studies were performed in 112 over-
eight or obese patients without organic heart disease and
n 36 normal-weight control patients. A subset of patients
ad overnight polysomnography performed to quantify the
everity of sleep apnea. An important control group con-
isting of normal-weight patients with documented sleep
pnea was also studied. Although RV volumes and wall
hickness were increased in the obese group, the RV ejection
ractions were not different between obese and normal-
eight patients. However, the tissue Doppler measure-
ents of tricuspid annular velocities in systole and
iastole and the RV strain indices were reduced in the
bese patients, particularly those with the highest BMIs.
he tissue Doppler velocities had an inverse and indepen-
ent relationship with BMI but were unrelated to the
everity of sleep apnea. The normal-weight patients with
leep apnea did not have tissue Doppler evidence of RV
ysfunction.
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Editorial Comment February 7, 2006:617–9A surprise from this study is that RV ejection fraction
n severely obese patients was normal and only relatively
ild changes in RV systolic function were detected using
issue Doppler imaging. These findings are very similar to
hose reported previously with respect to LV function in obese
atients (8,9). Likewise, RV diastolic function as assessed by
ricuspid annular diastolic velocities was also only mildly
mpaired in severe obesity. Taken together, the accumulat-
ng data call into question the widely held perception that
besity is independently associated with a cardiomyopathy
er se. It seems somewhat unlikely that this subtle degree of
ysfunction is a cause of overt heart failure. Perhaps over
onger periods of time more severe abnormalities of systolic
nd diastolic function are likely to develop. However, the
urrent data did not show a relationship between duration of
besity and the severity of RV dysfunction. In addition, the
agnitude of LV dysfunction detected by tissue Doppler in
younger group and an older group of obese patients were
omparable (6,8). Thus, the available evidence does not
upport the notion that LV dysfunction progresses over
ime in severe obesity.
Despite the fact that the myocardial abnormalities were
elatively mild, there were significant correlations between the
easures of RV function and maximal exercise tolerance. This
nding makes the case that the abnormalities seen on tissue
oppler imaging are clinically relevant. Moreover, the
resent results reinforce the notion that the ejection fraction
of either ventricle) is an insensitive measure of systolic
ysfunction, whereas tissue Doppler measurements are
ore sensitive for detecting such abnormalities (12,13). In
ddition, the high signal-to-noise ratio of tissue Doppler
easurements makes them easier to record, relatively simple
o quantify, and very reproducible as compared with ap-
roaches that require clear endocardial visualization. Lastly,
issue Doppler measurements are advantageous because
hey take into account the longitudinal component of
ontraction (which may be particularly important for the
ight ventricle) and do not require any geometric assump-
ions. They will likely become the standard method of
ssessing RV function.
Additional unexpected findings are seen in this study.
everely obese patients, even those with significant sleep
pnea, have very little tricuspid valve regurgitation. Those
hat do have tricuspid regurgitation seem to have fairly
ormal pulmonary artery systolic pressures. Not only do
hese findings show a surprising degree of adaptation to an
xtreme physiological condition, but they also suggest that
V filling pressures are not elevated enough to cause passive
ulmonary hypertension. The notion that LV filling pres-
ures may be fairly normal in extreme obesity is also
upported by the findings of normal E/E= values in obese
atients (8,9) and brain natriuretic peptide levels that are
educed compared with those in lean patients (14). Of note,
revious findings from the Framingham Heart Study sug-
est that the prevalence of valvular insufficiency is lower in
bese patients than in normal-weight people (15).With the rapid increase in the prevalence and severity of
besity around the globe, it is extraordinarily important to
etter understand this condition and its effects on the heart.
iven the interesting new data by Wong et al. (11), are we
loser to this goal? Their findings, taken in context with
ther recent publications, convincingly show that obesity is
onsistently associated with mild but significant reductions
n systolic and diastolic function of both left and right
entricles. The severity of the dysfunction is related to the
agnitude of obesity. Comorbidities are not prerequisites
or the presence of myocardial contractile abnormalities.
onetheless, the current data do not prove that obesity
irectly leads to heart failure, nor do they help us to
etermine the future risk of heart failure in individual obese
atients. Moreover, the incidence of heart failure has not
ncreased at pace with the profound increase in obesity in
ur society. If obesity serves in large part as a risk factor
or the development of coronary disease, then it makes sense
hat there would be a substantial lag between an increase in
he incidence of obesity and a subsequent escalation of heart
ailure. Alternatively, there may be a distinct, but very slow
20 years) progression of myocardial dysfunction in obe-
ity. In either case, it seems that there may be a window of
pportunity for treating related pathologies (i.e., hyperten-
ion) and preventing the final culprits in the pathogenesis of
besity-related heart failure (i.e., coronary artery disease).
s yet, we do not know to what extent the myocardial
ysfunction is reversible with weight loss. Lastly, before
ondemning the ill effects of obesity, we must ponder the
onsiderable body of data showing improved survival in
bese patients with heart failure or acute coronary syn-
romes (the obesity paradox) (16). Perhaps the cardiac
ypertrophy and mild dysfunction are the price that is
aid in exchange for the cardioprotective effects that have
onsistently been reported in obese patients. It would
ehoove us to consider the possibility that some aspect of
besity may precondition the heart against subsequent
nsults.
eprint requests and correspondence: Dr. Sheldon E. Litwin,
niversity of Utah Hospital, 4A100 SOM, 30 North 1900 E, Salt
ake City, Utah 84132. E-mail: Sheldon.Litwin@hsc.utah.edu.
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